Transcriptase in Biological Technology
Navigation Links
Transcriptase in Biological Technology
-- Lead NNRTI RDEA806 to begin Phase 2b trial in the second quarter of 2008 --
MONTREAL and SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Ardea
Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data was
presented on the Company's next generatio...
SAN DIEGO, April 7, 2008 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that data will be presented on its second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), at the 21st International Conference on Antiviral Research (ICAR). Addition...
- Activity data on lead NNRTI, RDEA806, and next generation compounds to be discussed - CARLSBAD, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data on the Company's non-nucleoside reverse transcri...
Purpose In clinical research, the monitoring of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is of significant interest due to the importance of assessing inter-individual and intra-individual metabolism variability. ...
Transcriptor Reverse Transcriptase is a new recombinant reverse transcriptase (RT) expressed in E. coli. The enzyme has RNA-directed DNA polymerase activity, DNA-dependent DNA polymerase activity, unwinding activity, an...
...dates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation N...
...dates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation N...
... cells, preventing infection. Finally, the third and most potent activity of the product will prevent the critical action of the virus-encoded reverse transcriptase inside the cell. Key features of the development program include the formulation of the product for delivery as gels or intravaginal rings, pharmacoki...
...hyperuricemia. RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 studi...ur most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. W...
...on in the first quarter of 2008 from $120 million in the same period in 2007. -- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, increased 21% to $273 million in the first quarter of 2008 from $226 million in the same period in 2007. U...
...s across its virology portfolio, including the phase III program for its lead compound, apricitabine (ATC), an anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI) class. ATC has successfully completed the 48 week dosing of its Phase 2b trial and the Phase 3 program has been initiated. Avexa plan...
...studies on three or more compounds this year. These compounds include RDEA806 and lead compounds from our 900 series, which are non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV, and RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory...
SAN DIEGO, April 7, 2008 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that data will be presented on its second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), at the 21st International Conference on Antiviral Research (ICAR). Addition...
- Activity data on lead NNRTI, RDEA806, and next generation compounds to be discussed - CARLSBAD, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data on the Company's non-nucleoside reverse transcri...
Purpose In clinical research, the monitoring of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is of significant interest due to the importance of assessing inter-individual and intra-individual metabolism variability. ...
Recombinant HIV Reverse Transcriptase
More thermostable than AMV RT and M-MLV RT Excellent target to evaluate antiviral agents Highly sensitive enzyme for RT-PCR applications Ideal for reverse transcribing transcripts with...Transcriptor Reverse Transcriptase is a new recombinant reverse transcriptase (RT) expressed in E. coli. The enzyme has RNA-directed DNA polymerase activity, DNA-dependent DNA polymerase activity, unwinding activity, an...
Transcriptor Reverse Transcriptase
Increase Power and Sensitivity in cDNA Synthesis with the new Transcriptor Reverse Transcriptase With the new recombinant Transcriptor Reverse Transcriptase, you will ...A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis
...otide capture (NASBA-EOC). The VDS technology has an advantage of not requiring the use of specialized equipment; VetDetect utilizes real-time reverse transcriptase polymerase chain reaction (RT-PCR) and VetScreen employs the conventional gel-based RT-PCR technique. All three platforms are highly sensitive and spe...Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
...ate Tablets are the generic version of Gilead Sciences Inc.'s Truvada(R) Tablets. Truvada(R) is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI or "nuke") family and is used in combination with other medications to control HIV infection. Patients often use second-line therapie...Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
...n. Business Highlights Idenix successfully completed a phase I/II proof-of-concept study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus (HIV) in September 2008. In February 2009, the company announced that it had licen...Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
...ed approximately $60.1 million. 2008 Year-to-Date Business Highlights -- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving onc......dates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation N...
...dates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation N...
Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
...dates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation N...... cells, preventing infection. Finally, the third and most potent activity of the product will prevent the critical action of the virus-encoded reverse transcriptase inside the cell. Key features of the development program include the formulation of the product for delivery as gels or intravaginal rings, pharmacoki...
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
...n. 2008 Year-to-Date Business Highlights -- Idenix has reported positive data from an ongoing phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of appr...Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting
...Session Presentation Title: RDEA806, a Novel HIV Non-Nucleoside Reverse transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients Ses...ur most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for th...Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference
...any's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunode...ty of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients" Se...ent candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully complete...Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
...s in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation N...Craig Johnson Joins Ardea Biosciences' Board of Directors
...s in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA......hyperuricemia. RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 studi...ur most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. W...
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
... in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment of......on in the first quarter of 2008 from $120 million in the same period in 2007. -- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, increased 21% to $273 million in the first quarter of 2008 from $226 million in the same period in 2007. U...
Ardea to Present at Cowen and Company's 28th Annual Health Care Conference
...l development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout.......s across its virology portfolio, including the phase III program for its lead compound, apricitabine (ATC), an anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI) class. ATC has successfully completed the 48 week dosing of its Phase 2b trial and the Phase 3 program has been initiated. Avexa plan...
Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
...l development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout....Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
...l development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout....Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference
...l development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
...l development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
...dication INTELENCE (etravirine) tablets -- the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adul...ons that partially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness. As with other HIV medicatio...Ardea Biosciences Announces $40 Million Private Placement
... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a mitogen-act...Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a mitogen-act...Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
...nteraction clinical studies of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV, in August of 2007; -- Presentation of four ...this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase ...New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
...diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...Ardea Biosciences Announces Changes to Research Management
...diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
...rate on what we believe is most critical to our future success -- building and advancing our pipeline." Idenix currently has a non-nucleoside reverse transcriptase inhibitor (NNRTI), IDX899, for the treatment of HIV-1 that is being evaluated in phase I/II clinical testing. The company also has a comprehensive HCV......studies on three or more compounds this year. These compounds include RDEA806 and lead compounds from our 900 series, which are non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV, and RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory...
QIAGEN LongRange PCR and 2Step RT-PCR Kits
...ption with no optimization required. The novel RNase H activity quencher binds to the cDNA:RNA hybridbinding site of the reverse transcriptase preventing degradation of the RNA during synthesis and enabling generation of full-length cDNA (Figure 3). The LongRange 2Step R...Counting FlashPlates on the Wallac MicroBeta
... FlashPlate and ScintiPlate. APPLICATION I A Reverse transcriptase Assay was performed using a Streptavidin coated FlashPlate (SMP103). In this assay, a biotinylated DNA oligonucleotide acts as a primer for reverse transcriptase (RT) on an RNA template. The signal is generated by incorporation of labele...Simple Approaches for Optimization of RT-PCR
...PCR Kit (PN 78355), and RT Script Kit (PN 78360) are based on M-MLV Reverse transcriptase (4) and Taq DNA Polymerase (5) . M-MLV Reverse transcriptase is useful in RT-PCR due to its naturally low RNase H activity (2). The kit...Other TagsOther Contentscommunitycommunitycommunitycommunitycommunitycommunitycommunitycommunitycommunitycompanioncompanioncompanioncompanioncompanioncompanioncomparativecomparativecomparativecomparativecomparativecomparativecomparativecomparativecompetentcompetentcompetentcompetentcompetentcompetentcomplementcomplementcomplementcomplementcomplementcomplementcomplementcomplementcomplementcomplementarycomplementarycomplementarycomplementarycomplementarycomplementarycomplementarycomplementarycompositecompositecompositecompositecompositecompositecomplementationcomplementation
HyperinsulinismHypersplenismHypermobileHyperopiaHyperparathyroidismHyperplasiaHyperthyroidHyperthyroidismHypertrophyHypnoticHypochondriaHyperuricemiaHyperventilationHypervitaminosis
(Date:12/11/2009)... species of wild apples that could be an ancestor ... and Central Asia. A new study comparing the diversity ... Georgia and Armenia with previously collected varieties originating in ... a core collection that will make M. orientalis ... , To identify and record the genetic diversity of ...
(Date:12/11/2009)... does a cell manage to identify and degrade the ... body against serious diseases? The researchers Sabine C. Horn, ... Jarosch of the Max Delbrck Center for Molecular Medicine ... in this puzzle. In an enzyme complex that plays ... they discovered a scaffold regulating the identification and disposal ...
(Date:12/11/2009)... in French . , Montreal, December ... molecular mechanism that prevents cancer. In the December 11 ... scientists from the Universit de Montral and the Universit ... molecule prevents the cancer-causing activity of cytokines, hormones that ... Crohns, in smokers and people exposed to asbestos. ...
Breaking Biology News(10 mins):Understanding apples' ancestors 2MDC researchers identify a scaffold regulating protein disposal 2Scientists identify natural anti-cancer defenses 2Susies Big Adventure Explores Plastic Surgery In Saudi Arabia 53959 1Steroid Can Ease Severe Sore Throat 53956 1Steroid Can Ease Severe Sore Throat 53956 2Steroid Can Ease Severe Sore Throat 53956 3Insulet Corporation to Present at Upcoming Investor Conferences 53953 1Insulet Corporation to Present at Upcoming Investor Conferences 53953 2(Date:12/15/2009)... premier manufacturer of Spa, Massage, and Medical tables announces its ... adjustable breast comfort system to ease pressure felt while laying ... ... New Freedom, Pennsylvania (PRWEB) December 15, 2009 -- OAKWORKS®, Inc., ... today announced the launch of the Utopian Massage Table with ...
(Date:12/15/2009)... , ... (PRWEB) December 10, 2009 -- Millions of men and women suffer ... clusters of red, blue or purple veins that spider-web across the nose, ... US, it’s been estimated that 25-30% of women and 10-20% of men ... Veinwave has been available for over 8 years in Europe ...
(Date:12/15/2009)... 15 "The entire San Diego Hospice and ... of Sol Price on December 14, 2009. Mr. Price ... loyalty and ethics in his business, community and personal ... who truly understood the responsibility of philanthropy and the ... will live on through his countless philanthropic efforts. We ...
(Date:12/15/2009)... in the Dec. 15 issue of the ... significant associations exist between parent-reported insomnia symptoms and ... young school-aged children. , Results of multivariate ... times more likely in children with gastrointestinal regurgitation ... headaches. Nineteen percent of children met the ...
(Date:12/14/2009)... New Research Focuses on Unmarried Young Adults, Attitudes and ... ,, WASHINGTON, Dec. 15 Nearly all unmarried ... should be planned (94% of men and 86% of ... pregnancy in their lives right now (86% of men ... by The National Campaign to Prevent Teen and Unplanned ...
Breaking Medicine News(10 mins):Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 2Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 3Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 4Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3[0] Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table[0] Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device [1] San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price[1] Insomnia symptoms linked with medical complaints in young school-aged children[1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |